JP2023507741A5 - - Google Patents
Info
- Publication number
- JP2023507741A5 JP2023507741A5 JP2022537012A JP2022537012A JP2023507741A5 JP 2023507741 A5 JP2023507741 A5 JP 2023507741A5 JP 2022537012 A JP2022537012 A JP 2022537012A JP 2022537012 A JP2022537012 A JP 2022537012A JP 2023507741 A5 JP2023507741 A5 JP 2023507741A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- isolated nucleic
- acid according
- composition
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025135462A JP2025166191A (ja) | 2019-12-20 | 2025-08-15 | ハンチントン病を処置するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951582P | 2019-12-20 | 2019-12-20 | |
| US62/951,582 | 2019-12-20 | ||
| PCT/US2020/066039 WO2021127455A1 (en) | 2019-12-20 | 2020-12-18 | Methods for treating huntington's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135462A Division JP2025166191A (ja) | 2019-12-20 | 2025-08-15 | ハンチントン病を処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023507741A JP2023507741A (ja) | 2023-02-27 |
| JP2023507741A5 true JP2023507741A5 (enExample) | 2023-12-06 |
| JP7730327B2 JP7730327B2 (ja) | 2025-08-27 |
Family
ID=76478540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537012A Active JP7730327B2 (ja) | 2019-12-20 | 2020-12-18 | ハンチントン病を処置するための方法 |
| JP2025135462A Pending JP2025166191A (ja) | 2019-12-20 | 2025-08-15 | ハンチントン病を処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135462A Pending JP2025166191A (ja) | 2019-12-20 | 2025-08-15 | ハンチントン病を処置するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230340470A1 (enExample) |
| EP (1) | EP4076656A4 (enExample) |
| JP (2) | JP7730327B2 (enExample) |
| CN (1) | CN115443339B (enExample) |
| AU (1) | AU2020407119A1 (enExample) |
| CA (1) | CA3163034A1 (enExample) |
| WO (1) | WO2021127455A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023211606A1 (en) * | 2022-01-27 | 2024-07-11 | AskBio Inc. | Compositions for treating neurological disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003084977A1 (en) * | 2002-04-04 | 2003-10-16 | Xiao Xiao | Gene expression control system and its use in recombinant virus packaging cell lines |
| US8795987B2 (en) * | 2005-02-11 | 2014-08-05 | International Business Machines Corporation | Ribonucleic acid interference molecules of Oryza sativa |
| EP2325315B1 (en) * | 2005-10-28 | 2014-05-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
| EP2422819B1 (en) | 2006-01-26 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
| US9920317B2 (en) * | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| MX391904B (es) | 2013-11-11 | 2025-03-12 | Sangamo Biosciences Inc | Un represor genetico para usarse en el tratamiento de la enfermedad de huntington. |
| BR112016025849A2 (pt) * | 2014-05-08 | 2017-10-17 | Chdi Foundation Inc | métodos e composições para o tratamento da doença de huntington |
| AU2015274457A1 (en) * | 2014-06-11 | 2017-01-05 | Circuit Therapeutics, Inc. | Optogenetic therapies for movement disorders |
| US10457940B2 (en) * | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| WO2019217483A1 (en) * | 2018-05-07 | 2019-11-14 | Spark Therapeutics, Inc. | Plasmid free aav vector producing cell lines |
| EP4022057A1 (en) | 2019-08-27 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of disorders associated with repetitive dna |
-
2020
- 2020-12-18 JP JP2022537012A patent/JP7730327B2/ja active Active
- 2020-12-18 EP EP20903638.3A patent/EP4076656A4/en active Pending
- 2020-12-18 US US17/786,932 patent/US20230340470A1/en active Pending
- 2020-12-18 WO PCT/US2020/066039 patent/WO2021127455A1/en not_active Ceased
- 2020-12-18 AU AU2020407119A patent/AU2020407119A1/en active Pending
- 2020-12-18 CN CN202080097236.5A patent/CN115443339B/zh active Active
- 2020-12-18 CA CA3163034A patent/CA3163034A1/en active Pending
-
2025
- 2025-08-15 JP JP2025135462A patent/JP2025166191A/ja active Pending